Skip to main
CNTB

CNTB Stock Forecast & Price Target

CNTB Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Connect Biopharma Hldgs is a promising investment opportunity for investors seeking exposure to the respiratory disease market due to its innovative treatment, positive clinical results, and experienced leadership.

Bears say

Connect Biopharma Hldgs is currently trading at a discounted value due to challenges in securing an established registrational pathway for its next-generation antibody rademikibart targeted towards interleukin-4-receptor alpha in the treatment of acute exacerbations of asthma and COPD, despite management's plans to propose Day 7 FEV1 as the Phase 3 primary endpoint. Investment risk also lies in the potential for the FDA to request an earlier time point, FEV1 AUC, or additional clinical outcomes. Despite positive data in China for atopic dermatitis and differentiation from dupilumab, the company's equity setup remains complicated, and its stock reaction will have implications for dilution and funding for future stages of development.

CNTB has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Connect Biopharma Holdings (CNTB) Forecast

Analysts have given CNTB a Strong Buy based on their latest research and market trends.

According to 7 analysts, CNTB has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Connect Biopharma Holdings (CNTB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.